Increased lung vascular permeability is an important contributor to respiratory failure in acute lung injury (ALI). We found that a function-blocking antibody against the integrin ␣v␤5 prevented development of lung vascular permeability in two different models of ALI: ischemia-reperfusion in rats (mediated by vascular endothelial growth factor [VEGF]) and ventilation-induced lung injury (VILI) in mice (mediated, at least in part, by transforming growth factor-␤ [TGF-␤]). Knockout mice homozygous for a null mutation of the integrin ␤5 subunit were also protected from lung vascular permeability in VILI. In pulmonary endothelial cells, both the genetic absence and blocking of ␣v␤5 prevented increases in monolayer permeability induced by VEGF, TGF-␤, and thrombin. Furthermore, actin stress fiber formation induced by each of these agonists was attenuated by blocking ␣v␤5, suggesting that ␣v␤5 regulates induced pulmonary endothelial permeability by facilitating interactions with the actin cytoskeleton. These results identify integrin ␣v␤5 as a central regulator of increased pulmonary vascular permeability and a potentially attractive therapeutic target in ALI.
CLINICAL RELEVANCE
We describe a novel role for integrin ␣v␤5 in regulating lung vascular permeability and agonist-induced endothelial permeability. Furthermore, we suggest that ␣v␤5 regulation of the actin-cytoskeleton may be a mechanism responsible for these effects.
tinct, and the precise role of VEGF in ALI remains controversial, we hypothesized that ␣v␤5 could be an important regulator of vascular permeability in the lung. Therefore, we sought to determine whether ␣v␤5 could regulate lung vascular permeability in in vivo models of ALI.
In this report, we used two in vivo models of ALI to examine the role of ␣v␤5 in regulating lung vascular permeability: ischemiareperfusion (IR)-induced and ventilator-induced lung injury (VILI). IR-induced lung injury is a significant clinical problem in cardiac surgery and, in particular, with lung transplantation (6) . Although the pulmonary edema associated with lung transplantation is often mild and self-limiting, graft dysfunction attributed to IR can occur in up to 20% of patients, leading to prolonged post-transplant length of hospitalization and increased post-transplant mortality (7) . Mechanical ventilation, while considered an essential tool for managing patients with respiratory failure, is now itself recognized, when administered at high tidal volumes, as an important contributing factor to the development of pulmonary edema (VILI) (1, 8, 9) .
Our studies show that ␣v␤5 regulates lung vascular permeability in models of both IR and VILI. However, in the lung, as opposed to what has been described in the systemic vasculature (5), ␣v␤5 regulation of vascular permeability is not restricted to VEGF-induced effects alone; in pulmonary vascular endothelial cells, both genetic absence and blockade of ␣v␤5 prevented monolayer permeability induced by three very different edemagenic agonists-VEGF, TGF-␤, and thrombin. Previous studies have identified the induction of actin stress fibers as an important step in regulating agonist-induced increases in endothelial paracellular permeability (10) (11) (12) (13) (14) (15) (16) . Stress fiber formation induced by all three agonists was attenuated by blockade of ␣v␤5, suggesting a mechanism for how ␣v␤5 might regulate paracellular endothelial permeability in the lung downstream of multiple signaling pathways. Understanding how ␣v␤5 regulates pulmonary endothelial permeability could provide valuable insights into mechanisms regulating lung vascular permeability and could identify this integrin as a promising target for the treatment of ALI.
MATERIALS AND METHODS

Reagents and Antibodies
VEGF (R&D Systems, Minneapolis, MN), TGF-␤ (R&D Systems), thrombin (Amersham Biosciences, Piscataway, NJ), RhoA kinase (ROCK) inhibitor (Y-27632) (Calbiochem, San Diego, CA), VEGF receptor II-Ig chimera adenovirus (AdVEGFRII-Ig) (generous gift from Richard C. Mulligan, Harvard School of Medicine [17] , Boston, MA), green fluorescent protein (GFP) adenovirus control (AdGFP) (generous gift from George Davis, Texas A&M University, College Station, TX), anti-integrin ␣v␤6 antibody (3G9) and TGF-␤ type II receptor IgG chimera (TGF-␤-RII-Ig) (generous gifts from Paul Weinreb, Biogen Idec, Cambridge, MA), IgG2b isotype antibody: mouse anti-human low-density receptor (LDL) receptor antibody (CRL-1691, clone C7; American Type Culture Collection [ATCC], Manassas, VA), anti-integrin ␣v␤3 antibody (AP-3) (HB-242, ATCC), anti-integrin ␣v␤3 blocking antibody (LM609) (Chemicon, Temecula, CA), anti-integrin ␣v␤8 antibody (37E.1) (generous gift from Steve Nishimura, University of California, San Francisco, CA), collagenase A (Sigma, St. Louis, MO), heparin (Sigma), M-450 Dynabeads (Dynal, Carlsbad, CA), anti-Fc␥ receptor II/III antibody (BD Pharmingen, San Jose, CA), anti-intracellular adhesion molecule (ICAM)-2 antibody (BD Pharmingen and Santa Cruz Biotechnology, Santa Cruz, CA), platelet endothelial cell adhesion molecule (PECAM, CD-31) (BioLegend, San Diego, CA), anti-vascular endothelial (VE)-cadherin antibody (Santa Cruz Biotechnology), anti-CD34 antibody (BD Pharmingen), 125 I-labeled albumin (Jeanatope ISO-TEX Diagnostics, Friendswood, TX), 14 C-bovine serum albumin (BSA) (Perkin-Elmer, Wellesley, MA).
␤5 Subunit Knockout Mice (␤5؊/؊)
129/svJae background ␤5 subunit knockout mice were generated and maintained in our laboratory as previously described (18) .
Anti-␣v␤5 Antibody
IgG2b isotype mouse monoclonal antibody against ␣v␤5 was raised and characterized as described in Results (Figure 1 ).
IR Lung Injury Model
Sprague-Dawley rats (300-500 g) (Charles River Laboratories, Wilmington, MA) were transtracheally intubated and ventilated under isoflurane anesthesia with a tidal volume of 6 ml/kg, positive end-expiratory pressure (PEEP) of 10 cm H 2 O, and 100% oxygen (Model 683; Harvard Apparatus Co., Holliston, MA). A median sternotomy was performed, heparin (200 IU) was injected into the right ventricle, and cannulas were placed in the pulmonary artery and left ventricle. Unilateral lung IR was induced by right pulmonary artery ligation for 30 min followed by release and reperfusion for 3 h. Rats were treated with antibodies intravenously immediately before the experiment (4 mg/kg) or with adenovirus intramuscularly 7 d before the experiment (10 10 pfu/kg). Previous studies have determined this to be the peak time for soluble VEGFRII secretion from the liver (19) . Contralateral lungs served as nonischemic controls.
VILI Model
Mice were transtracheally intubated and ventilated with a high tidal volume of 20 ml/kg at a rate of 48 breaths/min (without PEEP) for 4 h using a mouse ventilator (Model 683; Harvard Apparatus Co). Animals were anesthetized using serial ketamine (37.5 mg/ml) and xylazine (250 mg/ml) intraperitoneal injections (100 l/20 g) with equal volume injections of normal saline in matched animals. Matched nonventilated mice were administered equal volumes of anesthesia and saline to serve as baseline controls. Mice were administered antibodies by intraperitoneal injection 24 h before the experiment (4 mg/kg) or adenovirus intramuscularly 7 d before the experiment (10 10 pfu/kg) (19) . TGF-␤-RII-Ig (25 g in 100 l sterile saline) was administered intravenously immediately before initiation of ventilation. Lungs were harvested immediately after 4 h of ventilation for lung vascular leak assay preparation.
Quantification of VEGF-Induced Vascular Leak
Vascular leak was studied 7 d after intramuscular administration of 10 10 pfu/kg AdVEGFRII-Ig adenovirus (19) by measuring the extravasation of Evan's blue dye (30 mg/kg in 50 l per mouse). After 5 min, vascular leak was induced by dermal injection of VEGF (100 ng in 10 l normal saline) into mouse ears. After 1 h, 4 mm punch sections around the VEGF injection site were harvested and formamide-extracted dye was quantified as absorbance at 610 nm with a Spectra Max 190 Spectrophotometer (Molecular Devices, Sunnyvale, CA).
Lung Vascular Leak and Protein Permeability
0.5 Ci of 125 I-labeled albumin in 300 l sterile normal saline was administered intraperitoneally 4 h before lung harvest to ensure adequate distribution. After each experiment, a blood sample was obtained to measure the hemoglobin concentration and the water-to-dry weight ratio of blood for the extravascular plasma equivalents (EVPE) calculation. Lungs (left for IR, and bilateral for VILI) were homogenized and the extravascular lung water determined by calculating the water-todry weight ratio using the following equation: W/D ϭ Q wet /Q dry , in which Q wet is the difference between the water content of the lung homogenate and the water content of the blood in the lung, and Q dry is the dry lung weight calculated as the weight of the lungs minus the blood and water volumes in the lung. Lung endothelial permeability to albumin, expressed as EVPE in ml, calculated using the following equation: EVPE ϭ (C H -(C Pend ϫ Q B ))/C Pave. C H represents the 125 I counts/min/g in the homogenized lung, C Pend represents the counts/min/g in plasma at the end of the experiment, and C Pave represents the average counts/min/g in the plasma samples at the end of the experiment. Q B is the blood volume in the lungs determined by the gravimetric method using weights from wet and dried lung homogenates (19, 20) . Counts were measured on a Wizard ␥ counter (Perkin-Elmer). Control lungs included the contralateral nonischemic, nonreperfused right lung for IR, and lungs from nonventilated mice for VILI. Baseline lungs for IR were harvested from animals not subject to pulmonary artery ligation.
Cell Lines
Human pulmonary artery endothelial cells (HPAECs) (passages 3-9) (Clonetics, Walkersville, MD) were maintained in EBM-2 basal endothelial media supplemented with EGM-2 supplemental aliquots (Clonetics). Bovine pulmonary artery endothelial cells (BPAECs) (passages all Ͻ 10) (CCL-209, ATCC) and mouse pulmonary endothelial cells (see Isolation of Primary Mouse Endothelial Cells from ␤5 Subunit Knockout Mice below) were cultured in Dulbecco's minimal essential (DME)/F-12 medium supplemented with 20% fetal bovine serum (FBS), 50 mg/liter of endothelial mitogen (Biomedical Technologies, Stoughton, MA), and 10,000 U/liter of heparin. Cells were maintained on Corning polystyrene culture dishes (Fisher Scientific, Pittsburgh, PA) coated with type VI collagen (Sigma) and seeded onto surfaces pre-coated with vitronectin (Upstate Biotechnology, Charlottesville, VA), fibrinogen (Calbiochem), or recombinant TGF-␤1 latency-associated peptide (LAP) (21) or onto collagen-coated transwells (Corning, Corning, NY) as required for individual experiments. Human SW480 cells (CCL-228, ATCC) were infected with a retrovirus to express full-length integrin ␤3 (pBABE-puro-␤3) or transfected with the plasmid vector pcDNA1-neo-␤6 to express full-length ␤6 (SW480-␤3 and SW480-␤6 cells). SW480-␤8 cells were a generous gift from Steve Nishimura, University of California, San Francisco. SW480 cells were maintained in DMEM supplemented with 10% FBS and an appropriate selection marker (Geneticin [G418, Life Technologies, Inc., Carlsbad, CA] or puromycin [Calbiochem] ).
Cell Adhesion Assay
Cells were allowed to adhere for 1 h to wells coated with a range of concentrations of specific ligand in the presence of control IgG antibody, saline, or the tested blocking antibody. Bovine serum albumin (BSA)-coated wells served as nonadhesion controls. Plates were then spun topside down at 40 ϫ g to remove nonadherent cells, and the remaining cells were fixed with formalin, stained with crystal violet, and quantified by absorbance (595 nm).
Isolation of Primary Mouse Endothelial Cells from ␤5 Subunit Knockout Mice
Lung tissue was collected from ␤5 subunit knockout mice, pureed, digested with 0.1% collagenase A, filtered through 10-m nylon mesh, centrifuged, and plated. At 16 h, negative selection was performed with M-450 Dynabeads pre-conjugated with anti-Fc␥ receptor II/III antibody. Positive selection with Dynabeads pre-conjugated with anti-ICAM-2 antibody was performed on Days 3 and 7. To assess purity, (E ) SW480-␤3 cell adhesion to a range of concentrations of fibrinogen was determined in the presence of ALULA (10 g/ml). ␣v␤3-specific blockade of adhesion was achieved using ␣v␤3 blocking antibody (LM609). Data shown are the means Ϯ SE, n ϭ 3. (F ) ␤5 knockout mouse pulmonary endothelial cells (␤5Ϫ/Ϫ) and ␤5 knockout mouse pulmonary endothelial cells expressing fulllength human ␤3 (␤5Ϫ/Ϫ[␤3]) were assessed with flow cytometry using ALULA and anti-␣v␤3 antibody (AP-3). (G ) SW480-␤6 cell adhesion to a range of concentrations of TGF-␤1-latency-associated peptide (LAP) was determined in the presence of ALULA (10 g/ml). ␣v␤6-specific blockade of adhesion was achieved using ␤6-blocking antibody (3G9). Data shown are the means Ϯ SE, n ϭ 3. (H ) SW480-␤6 cells were assessed with flow cytometry with biotinylated anti-␣v␤6 antibody (Biotin-3G9) at different concentrations (2 g/ml, 0.2 g/ml, and 0.02 g/ml) (solid histograms) and reassessed with P1F6 competitive binding (100 g/ml). Controls (no primary antibody) are shown as open histograms.
cells were analyzed for expression of ICAM-2 and PECAM by flow cytometry (FACSort; Becton Dickinson, Franklin Lakes, NJ) and CD34 and VE-cadherin by immunocytochemistry.
Conditional Immortalization of ␤5 Subunit Knockout and Wild-Type Mouse Pulmonary Endothelial Cells and ␤5 Reconstitution
Primary endothelial cells were transfected with the tsA58 SV40 large and small T antigen genome (pUC18-tsA58 SV40) (generous gift from Jiyue Zhu, Penn State College of Medicine, Hershey, PA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and repeatedly passaged for over 1 mo at 33ЊC to select for immortalized cells. Cells were incubated at 39ЊC for 24 h before all described experiments and before assessment for purity with endothelial cell markers (ICAM-2, VEcadherin, PECAM, and CD-34). Immortalized cells were infected with retrovirus expressing full-length ␤5 (pWZL-␤5) generated by subcloning ␤5 cDNA (Clone 5.1; ATCC) (22) into a pWZL-blast2 vector containing a blasticidin resistance gene.
Assay of Transendothelial Albumin Flux
Cells were seeded onto 6.5-mm collagen-coated PFTE membrane Costar Transwells (Fisher Scientific) at 75,000 cells per well and cultured to confluence. Cells were incubated with antibodies (10 g/ml) for 1 h and then stimulated with VEGF (30 ng/ml), TGF-␤ (10 ng/ml), or thrombin (10 U/ml) for 1 h.
14 C-BSA (0.005 Ci) (Perkin-Elmer) was applied to each upper compartment for 1 h at 37ЊC, after which contents from the lower compartment were collected and counted with an LS 6500 Multi-Purpose Scintillation Counter (Beckman, Fullerton, CA). Only monolayers retaining Ͼ 97% of tracer at baseline were studied.
Stress Fiber Visualization
Cells were grown on collagen-coated glass coverslips to confluence over 4 d. Serum-starved cells (12 h) were pre-treated with either control antibody or ALULA for 1 h, then stimulated with respective agonists (VEGF [30 ng/ml], TGF-␤ [10 ng/ml], or thrombin [10 U/ml]) for 10 min. Cells were then fixed with 3.7% paraformaldehyde for 10 min, permeabilized with 0.5% triton X-100, then stained with rhodamine phalloidin (Molecular Probes, Carlsbad, CA), mounted, and imaged using a Leica DM5000B microscope equipped for epifluorescence.
RhoA Activation Assay
Cells were grown on collagen-coated 100-mm culture dishes, serumstarved, stimulated, rinsed, and lysed per assay kit manufacturer's protocol (Upstate Biotechnology). After centrifugation, lysate supernatants were incubated with agarose beads conjugated with rhotekin Rhobinding domains (RBD) that recognize only GTP-bound active RhoA. RhoA was detected from pulled-down product by Western analysis using anti-RhoA antibodies (Upstate Biotechnology). GTP␥S and GDP-spiked lysates served as positive and negative controls.
RESULTS ␣v␤5 Antibody Characterization
To study the role of ␣v␤5 in regulating lung vascular permeability in rodent models of ALI, we needed an effective specific inhibitor of ␣v␤5 function that could recognize the specific rodent integrin. Therefore, we raised a monoclonal antibody against mouse ␣v␤5 (ALULA) by immunizing ␤5 subunit knockout mice with mouse L fibroblasts expressing ␣v␤5. We confirmed that ALULA functionally blocked mouse L cell adhesion to the ␣v␤5 ligand vitronectin ( Figure 1A ). ALULA has an identical immunoprecipitation profile to the previously validated anti-␣v␤5 antibody P1F6 (23) (Figure 1B) , and inhibits adhesion of human SW480 cells to vitronectin ( Figure 1C ). To exclude ALULA recognition of other ␣v-containing integrins, we performed binding site competition assays using the anti-␣v␤5 antibody, P1F6. Excess P1F6 completely inhibited binding of ALULA to mock-transfected SW480 cells, which express ␣v␤5 as their only ␣v integrin ( Figure  1D ). ALULA binding to SW480 cells transfected with human ␤3, ␤6, or ␤8 (SW480-␤3, -␤6, and -␤8) was similarly inhibited by P1F6 ( Figure 1D ). Furthermore, ALULA did not inhibit adhesion of SW480-␤3 to the ␣v␤3 ligand fibrinogen ( Figure  1E ) and did not recognize ␣v␤3 in ␤5 knockout pulmonary endothelial cells transfected with full-length human ␤3 ( Figure  1F ). ALULA was also incapable of inhibiting adhesion of SW480-␤6 cells to the ␤6 ligand TGF-␤1 LAP ( Figure 1G ). Anti-␣v␤6 antibody (3G9) binding to SW480-␤6 cells was not affected by excess P1F6 at any dilution of 3G9 tested ( Figure  1H ). ALULA also did not affect SW480-␤8 cell adhesion to TGF-␤1-LAP, but this finding is not straightforward to interpret because of the lack of available ␣v␤8 antibodies that inhibit cell adhesion for use as a positive control (data not shown). In addition to mouse and human ␣v␤5, ALULA was shown to recognize bovine ␣v␤5 by flow cytometry using bovine pulmonary artery endothelial cells (BPAECs) (data not shown).
␣v␤5 Regulates Lung Vascular Permeability in a Model of Lung IR-Induced ALI
We initially chose to study IR-induced lung injury in rats (24) since VEGF had been implicated as a possible mediator of increased lung vascular permeability after IR (25, 26) , and since ␣v␤5 had been shown to mediate VEGF-induced systemic vascular permeability (5). IR induced a robust increase in lung vascular permeability, as measured by parenchymal extravasation of an I 125 -albumin intravascular tracer, which was completely blocked by systemic administration of ALULA (Figure 2 ). To determine whether IR-induced lung vascular permeability was indeed dependent on VEGF, we used an adenovirus expressing a VEGF receptor II-IgG chimera (AdVEGFRII-Ig) that had previously been shown to be an effective blocker of VEGF effects in rodents (27) . Administration of AdVEGFRII-Ig blocked IR-induced lung vascular permeability, whereas a control adenovirus expressing green fluorescent protein (AdGFP) did not ( Figure 2 ).
␣v␤5 Regulates Lung Vascular Permeability in VILI
To determine whether the protective effect of blocking ␣v␤5 with ALULA could be generalized to other models of increased lung vascular permeability, and to take advantage of the availability of ␤5 knockout mice (18), we used a mouse model of VILI in which lung vascular permeability was induced by four hours of mechanical ventilation at a high tidal volume (20 ml/kg) (28) . This model produced a robust increase in lung vascular permeability, which was completely blocked by ALULA ( Figure  3A) . ␤5 subunit knockout mice were also completely protected from increased lung vascular permeability ( Figure 3A) . However, in contrast to our results from the IR model, AdVEGFRIIIg did not block lung vascular permeability induced by VILI. Adequate blockade of VEGF with AdVEGFRII-Ig was confirmed by the absence of dermal vascular leak after intradermal VEGF injection ( Figure 3B ). Since previous reports have associated the multifunctional cytokine TGF-␤ with VILI (29, 30) , and our own previous work has shown TGF-␤ to be an important mediator of lung vascular permeability induced by other stimuli (including the anti-cancer drug bleomycin and bacterial lipopolysaccharide [31] ), we examined the role of TGF-␤ in our VILI model. Administration of a recombinant TGF-␤ receptor II IgG chimera (TGF-␤RII-Ig) significantly inhibited lung vascular permeability in VILI ( Figure 3A ).
␣v␤5 Regulates Pulmonary Artery Endothelial Permeability Induced by Diverse Mediators of ALI
Our in vivo data suggested that the protective effects of blocking ␣v␤5 were not restricted to effects on VEGF-induced increases in vascular permeability. Since VEGF and TGF-␤ activate distinct families of receptors and trigger different initial signaling pathways, we hypothesized that ␣v␤5 might play a central regulatory role downstream of multiple agonist pathways. To test this hypothesis, we studied the effects of VEGF, TGF-␤, and also the serine protease thrombin, on pulmonary endothelial cell barrier permeability using a C 14 -albumin flux assay. Thrombin has been extensively studied for its potent effects on increasing pulmonary endothelial permeability (13, (32) (33) (34) (35) (36) . We stimulated both bovine pulmonary artery endothelial cell (BPAEC) ( Figure  4A ) and human pulmonary artery endothelial cell (HPAEC) ( Figure 4B ) monolayers with VEGF, TGF-␤, and thrombin and found that dose-dependent increases in transendothelial C 14 -albumin flux in response to each agonist were blocked by ALULA.
Genetic Absence of ␣v␤5 in Pulmonary Endothelial Cells Protects against Permeability Induced by Diverse Mediators of ALI
To confirm specificity of this effect to ␣v␤5, we used ␤5 knockout pulmonary endothelial cells isolated from ␤5 knockout mice. Primary mouse ␤5 knockout cells were conditionally immortalized by retroviral transfer of a temperature-sensitive SV40 large and small T antigen transgene. ␤5 reconstitution was performed by retroviral transfer of full-length human ␤5 into the immortalized ␤5 knockout cells. ␤5 expression and endothelial cell characteristics were confirmed by immunocytochemistry and flow cytometry ( Figures 4C-4D ). ␤5 knockout cells were completely resistant to increases in endothelial permeability induced by all three agonists ( Figure 4E ). As seen in both BPAECs and HPAECs, VEGF, TGF-␤, and thrombin each induced dose-dependent increases in monolayer permeability in ␤5 reconstituted mouse pulmonary endothelial cells ( Figure 4E ). ␤5 reconstituted cells incubated with ALULA were resistant to agonist-induced permeability changes ( Figure 4E ).
␣v␤5 Regulates Agonist-Induced Stress Fiber Formation in BPAECs
Filamentous (F)-actin can be induced to polymerize to form transcytoplasmic cables that generate tension between cell-cell junctions and focal adhesions on the extracellular matrix. Subsequent disruption of cell-cell junctions can lead to increased paracellular permeability. To test whether agonist-induced stress fiber formation could be regulated by ␣v␤5, we stimulated monolayers of BPAECs, treated with ALULA or control antibody, with the agonists VEGF, TGF-␤, and thrombin. As has previously been reported (10) (11) (12) (13) (14) (15) (16) , each of these agonists caused dramatic increases in actin stress fiber formation. Furthermore, in each case, this effect was markedly attenuated by ␣v␤5 blockade with ALULA compared with treatment with control antibody ( Figure 5A ).
Agonist-Induced Stress Fiber Formation and Permeability in BPAECs Are Blocked by RhoA Kinase Inhibition
The RhoA family of GTPases has been shown to be a critical regulator of actin stress fiber formation (37-39) as well as an important regulator of increased endothelial permeability (32, 33, (40) (41) (42) (43) (44) (45) (46) (47) (48) . Each of the three agonists we used for these studies has previously been shown to activate RhoA (45, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) . We confirmed these findings by showing that inhibition of RhoAactivated kinase (ROCK) (immediate downstream effector of RhoA) prevents VEGF-, TGF-␤-, and thrombin-induced stress fiber formation ( Figure 5A ). Furthermore, we confirmed that agonist-induced changes in permeability were completely blocked by ROCK inhibition ( Figure 5B ).
Agonist-Induced RhoA Activation in BPAECs Is Unaffected by ␣v␤5 Blockade
To determine whether ␣v␤5 might regulate agonist-induced stress fiber and permeability changes at the level of RhoA activation, we used a rhotekin RhoA-binding domain (RBD)-based active RhoA assay, to assess global agonist-induced increases in cellular RhoA activity. Previous studies have shown that RhoA is activated by thrombin, VEGF, and TGF-␤ (45, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) . We found robust RhoA activation by thrombin in BPAECs that was completely unaffected by ␣v␤5 blockade ( Figure 5C ). This finding suggests that ␣v␤5 contributes to RhoA and ROCKmediated induction of stress fiber formation and increased endothelial permeability by acting downstream of RhoA.
DISCUSSION
Despite numerous advances in our understanding of the pathophysiology of ALI, specific molecular mechanisms responsible for this clinical syndrome remain poorly understood. In this report, we have characterized a novel and potentially critical role for integrin ␣v␤5 in the development of an important pathologic Figure 4 . ␣v␤5 regulates permeability of pulmonary endothelial monolayers induced by diverse mediators of ALI. (A ) Serumstarved confluent BPAEC monolayers on Transwells were incubated with ALULA or isotype control antibody (Control Ab) 1 h before stimulation with VEGF, TGF-␤, or thrombin at the doses shown. Transendothelial leak was determined by application of a C 14 -albumin tracer to the apical well and subsequent collection and scintillation counting of basolateral well contents after 1 h. Data shown are the means Ϯ SE, n ϭ 3. *P ϭ 0.013 for VEGF (30 ng/ml); **P ϭ 0.018 for TGF-␤ (10 ng/ml); ***P ϭ 0.022 for thrombin (10 U/ml) for cells treated with ALULA compared with those treated with Control Ab. (B ) Serum-starved confluent HPAEC monolayers on Transwells were incubated with ALULA or Control Ab 1 h before stimulation with VEGF, TGF-␤, or thrombin at the doses shown. Data shown are the means Ϯ SE, n ϭ 3. *P ϭ 0.038 for VEGF (30 ng/ml); **P ϭ 0.041 for TGF-␤ (10 ng/ml); ***P ϭ 0.050 for thrombin ( ) pulmonary endothelial cell monolayers seeded onto Transwells were assessed for monolayer permeability. ␤5 reconstituted cells were incubated with ALULA or a Control Ab (10 g/ml) 1 h before stimulation of both cell types with VEGF, TGF-␤, or thrombin at the doses shown. Data shown are the means Ϯ SE, n ϭ 3. *P ϭ 0.006 for VEGF (30 ng/ml); **P ϭ 0.004 for TGF-␤ (10 ng/ml); ***P ϭ 0.014 for thrombin 10 U/ml for ␤5Ϫ/Ϫ(␤5 Recon) cells treated with Control Ab compared with ␤5Ϫ/Ϫ cells.
† P ϭ 0.009 for VEGF (30 ng/ml); † † P ϭ 0.004 for TGF-␤ (10 ng/ml); † † † P ϭ 0.011 for thrombin (10 U/ml) for ␤5Ϫ/Ϫ(␤5 Recon) treated with ALULA compared with those treated with Control Ab.
hallmark of ALI-increased lung vascular permeability. Furthermore, ␣v␤5 regulates increased permeability in human, bovine, and murine pulmonary endothelial cells induced by a range of different edemagenic agonists including VEGF, TGF-␤, and thrombin. This is a particularly intriguing finding since a complex network of proinflammatory mediators, produced locally in the lung (by fibroblasts, inflammatory, epithelial, and endothelial cells), or derived from extrapulmonary sources, are thought to initiate and amplify the inflammatory response in ALI (31, 60, 61) .
Our studies have also identified ␣v␤5 as a specific regulator of induction of actin stress fibers, a well-described contributor to induced increases in pulmonary endothelial permeability. This finding suggests that ␣v␤5 might regulate changes in vascular permeability by coordinating interactions with the actin cytoskeleton. Integrins are known to be principal components of focal adhesions-multimolecular structures that link the extracellular matrix (ECM) to the intracellular cytoskeleton. Several reports have linked focal adhesions and regulation of the actin cytoskeleton to endothelial barrier function, but the precise molecular basis for this regulation remains unclear (62-65). Butler and coworkers recently reported that isolated focal adhesion complexes can initiate actin polymerization of actin monomers de novo (66) . Moreover, these investigators showed that actin polymerization is dependent on physical clustering of integrins to focal adhesion structures (66) . Additional studies are required to identify the molecular mechanisms by which ␣v␤5 regulates stress fiber formation.
Physical passage of solutes through the endothelial barrier is thought to occur via paracellular pathways or through receptoractivated transcytosis (67, 68) . The functional relevance, relative contribution, and molecular determinants of these distinct mechanisms remain incompletely understood, but it has been suggested that direct modification of the actin cytoskeleton in endothelial cells is important for increasing paracellular permeability. One frequently cited model describes paracellular gap formation as a consequence of imbalanced competition between cytoskeletal, adhesive cell-cell and cell-matrix forces (10, 16, 47, 69) . In this model, F-actin polymerizes and bundles into morphologically distinct "stress fibers". Actomyosin-mediated generation of tension leads to alteration of cell shape and formation of paracellular gaps. Stress fibers have been shown to form in endothelial cells stimulated by several vasoactive mediators (11-15, Figure 5 . Agonist-induced stress fiber formation in bovine pulmonary artery endothelial cells is attenuated by ␣v␤5 blockade and ROCK inhibition, but ␣v␤5 blockade has no effect on RhoA activity. (A ) Confluent monolayers of BPAECs were pretreated with either isotype control antibody (Control Ab) (10 g/ml), ALULA (10 g/ml), or ROCK inhibitor (Y-27632) (10 M) for 1 h, then stimulated with agonists VEGF (30 ng/ml), TGF-␤ (10 ng/ml), and thrombin (10 U/ml) for 10 min. Cells were fixed, permeabilized, and stained with rhodamin-phalloidin. (B ) Serumstarved confluent BPAEC monolayers on Transwells were incubated with ROCK inhibitor (Y-27632) (10 M) or vehicle control for 1 h before stimulation with VEGF, TGF-␤, or thrombin at the doses shown. Transendothelial leak was determined by application of a C 14 -albumin tracer to the apical well and subsequent collection and scintillation counting of basolateral well contents after 1 h. Data shown are the means Ϯ SE, n ϭ 3. *P ϭ 0.001 for VEGF (30 ng/ml); **P ϭ 0.005 for TGF-␤ (10 ng/ml); ***P ϭ 0.003, for thrombin (10 U/ml) for cells treated with Y-27632 compared with those treated with vehicle. (C ) Total cellular RhoA activation in was assessed using BPAECs pre-treated with either Control Ab (10 g/ml) or ALULA (10 g/ml), that were then stimulated for 2 min with thrombin (10 U/ml). Cell lysates were then incubated with agarose beads conjugated with rhotekin Rhobinding domains (RBD) that recognize only GTP-bound active RhoA (immunoprecipitation [IP]:Rhotekin). RhoA was detected from pulled-down product by immunoblot (IB) using anti-RhoA antibody (RhoA). Total lysate samples not incubated with rhotekin beads were immunoblotted with anti-RhoA antibody and served as total RhoA and loading controls.
70, 71), including VEGF, TGF-␤, and thrombin (45, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) . Although our studies did not directly distinguish between paracellular and transcellular pathways, the parallel ability of ␣v␤5 to regulate both stress fiber formation and transendothelial flux suggests that in our system the paracellular pathway may be the more relevant.
Use of cells derived from proximal pulmonary macrovascular endothelium is a limitation to our studies. Microvascular endothelial cells are thought to be a more anatomically and physiologically relevant model of pulmonary capillary leak and many studies have detailed significant physiologic differences between lung cells from microvascular and macrovascular bed origins (72) (73) (74) (75) (76) (77) (78) . Previously, the ␣v␤5-specific antibody P1F6 was shown to have no effect on ligand-induced increases in lung capillary hydraulic conductivity (79) . Our studies are different because we have focused on agonist-induced permeability events, rather than on effects of integrin ligand binding alone. In fact, we found no effect of ␣v␤5 blockade on baseline permeability or on lung permeability in uninjured animals. However, future studies using pulmonary microvascular endothelial cells, pulmonary microvascular endothelial and alveolar epithelial cell co-culture systems (80), or perhaps capillary split-drop techniques (79, 81) would be necessary to address the important issue of what role ␣v␤5 might play in regulating capillary permeability.
The model of VILI we used uses relative tidal volumes substantially larger than any currently used for ventilation of people. Therefore, results of the current study cannot be directly extrapolated to suggest that ␣v␤5 blockade would diminish increased permeability induced by volutrauma in mechanically ventilated patients. Nonetheless, this model is widely used and likely does reflect the effects of excess stretch on alveolar units. Determination of the direct relevance of our findings to patients with VILI will need to await clinical studies with drugs designed to target this integrin.
Several important unanswered questions remain, including how actin stress fiber formation is regulated by ␣v␤5 ligation. Our observations that ␣v␤5 antibody produced identical results to both ␤5 knockout mice and ␤5 knockout cells strongly suggest that the antibody exerted its effect by specifically inhibiting ␣v␤5 function, rather than as a result of other antibody-integrin interactions. VEGF, TGF-␤, and thrombin activate different families of receptors (tyrosine kinase, serine-threonine kinase, and G protein coupled, respectively) that initiate distinct proximal signaling pathways. It will be important to determine how these diverse pathways converge on ␣v␤5, and to identify common signaling intermediates. An example of such a signaling intermediate might be the RhoA small GTPase, which has been shown to be activated downstream to a variety of different agonist pathways (45, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) , and to be both a critical regulator of actin stress fiber formation (37) (38) (39) and increased endothelial permeability (32, 33, (40) (41) (42) (43) (44) (45) (46) (47) (48) . Our findings in this report suggest that total cellular RhoA activation is not directly affected by ␣v␤5 blockade, implying that RhoA activation occurs upstream of ␣v␤5.
While we have focused on disruption of the pulmonary endothelial cell barrier as the main target of ␣v␤5 effects, there are alternative targets to consider. In vivo increases in lung vascular permeability in ALI involve complex interactions between multiple cell types, including leukocytes and epithelial cells, as well as endothelial cells (82) . Since ␣v␤5 is widely expressed, it is possible that ␣v␤5-mediated effects on other cell types could contribute to the overall in vivo role of ␣v␤5 in regulating pulmonary edema formation. Our in vivo models were chosen primarily as models of increased lung vascular permeability. Relevance to ALI, and even to their specific clinical correlates may be questioned, for example, with experimental ischemia and reperfusion times (for IR) and brief relative ventilation periods and extreme tidal volume settings (for VILI). The complexities of ALI mandate that other models be tested. Ultimate proof of relevance will only come from clinical studies in patients at risk for or affected by ALI.
Finally, although our results demonstrate an important role for ␣v␤5 ligation in regulating pulmonary endothelial permeability, they do not identify the relevant in vivo ligand. Our cell culture studies were performed by seeding cells onto nonspecific collagen substrates in the presence of fetal calf serum, a rich source of vitronectin, and growing them in serum-enriched media over several days. This protocol allowed ample time for vitronectin to bind to the cells and substrate and for the cells to secrete additional ECM proteins. Our ␣v␤5 blocking antibody, ALULA, specifically recognizes ␣v␤5 and blocks adhesion to vitronectin in vitro. However, it is certainly plausible that, in vivo, other ligands are critical for the functions we have described. While vitronectin knockout mice have been observed to be viable and healthy (83) , and therefore, would be a good model system to determine relevance of vitronectin, these studies might potentially be confounded by effects exerted by the integrin ␣v␤3, which shares vitronectin as a common ECM protein ligand.
Despite these gaps in our current understanding, the findings reported here have potential clinical relevance. Given the robust regulatory effects of blocking ␣v␤5 in two quite different in vivo models of increased lung vascular permeability and in the pulmonary endothelial permeability response to multiple biologically relevant agonists, ␣v␤5 appears to be an attractive therapeutic target for ALI, a substantial cause of morbidity and mortality that is currently largely untreatable.
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